Tania Bekerman, Rac
About Tania Bekerman, Rac
Tania Bekerman is the Associate Director at Beigene in Cambridge, Massachusetts, with over 20 years of experience in regulatory affairs and pharmaceutical development.
Company
Tania Bekerman is currently working at Beigene as an Associate Director. She operates out of Cambridge, Massachusetts, United States. Beigene is known for its work in the development and commercialization of innovative cancer therapeutics.
Title
Tania Bekerman holds the position of Associate Director at Beigene. In this role, she utilizes her extensive experience in regulatory affairs and pharmaceutical development to guide regulatory strategies and ensure compliance with global regulatory requirements.
Employment History
Before joining Beigene, Tania Bekerman accumulated over 20 years of experience in regulatory affairs and pharmaceutical development. She worked at Pharmacyclics as Senior Manager, Regulatory Affairs from 2014 to 2019 in Sunnyvale, California. Prior to that, she held a regulatory role at Abbott between 2013 and 2014. At Corcept Therapeutics, she was Manager of Regulatory Affairs from 2008 to 2013. Earlier in her career, she worked at Alza Corporation and Johnson & Johnson, where she gained experience as a Regulatory Affairs Professional and Scientist, respectively. She began her career at Allergenics as a Pharm Development Scientist from 2000 to 2003.
Education and Expertise
Tania Bekerman obtained her Master of Science and Bachelor of Pharmacy degrees from The Hebrew University of Jerusalem. She furthered her education at the University of California, Santa Cruz. Her educational background has equipped her with a strong foundation in both regulatory affairs and scientific research, enabling her to excel in managing regulatory strategies for pharmaceutical products, especially in oncology.
Achievements
Throughout her career, Tania Bekerman has made significant contributions to the regulatory affairs field. She has a proven track record of successful regulatory filings with the FDA and EMA. Her expertise extends to navigating complex regulatory environments and contributing to the development and approval of several new drug applications (NDAs). She has led cross-functional teams in the preparation of regulatory submissions and has been involved in the lifecycle management of pharmaceutical products, including post-marketing activities.